12 Health Care Stocks Moving In Wednesday's After-Market Session
Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate
PMV Pharmaceuticals Announces Board Chair Transition
PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMV Pharma Q4 EPS $(0.34) Beats $(0.41) Estimate
PMV Pharmaceuticals shares are trading higher. The company announced that NEJM publication highlighted the antitumor activity of rezatapopt in advanced solid tumor-types establishing proof-of-concept for p53 reactivation.
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
PMV Pharmaceuticals Announces NEJM Publication Showing Phase 1 Rezatapopt Demonstrates Safety And Antitumor Activity In TP53 Y220C–Mutated Cancers
Caesarstone And 2 More Penny Stocks Worth Watching
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PMV Pharma Q3 EPS $(0.40), Inline
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
PMV Pharmaceuticals, Inc. (PMVP) Presents at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Slideshow
PMV Pharmaceuticals Says Updated Rezatapopt Data Show 46% Response Rate in Ovarian Cancer
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.